Background
==========

*CCL3L1* and*CCL4L1* are chemokine genes, located on chromosome 17q12 (Figure [1](#F1){ref-type="fig"}). They are copy number variable genes that share 95% sequence identity with their non-copy number variable paralogues *CCL3* and*CCL4*\[[@B1]\]. The copy number (CN) of these genes varies between populations \[[@B2]\] and has been shown to be associated with phenotypes, such as susceptibility to HIV infection \[[@B2]\] and SLE \[[@B3]\]. A*CCL3L1* pseudogene, also known as*CCL3L2,* is present in the*CCL3L1* region. This pseudogene has sequences similar to*CCL3L1* gene, but lacks exon 1 of*CCL3L1*^1^. As a result, its presence might affect copy number (CN) measurement and subsequent interpretations in association studies between*CCL3L1* CN and diseases \[[@B4]\]. The copy number of*CCL3L1/CCL4L1* was measured using paralogue ratio test (PRT) in 270 HapMap samples 192 UK samples and 157 Basques samples \[[@B5]\]. Firstly, we examined the association between the presence of the*CCL3L1* pseudogene and*CCL3L1* CN in the UK samples and HapMap samples by PCR. The pseudogene was found in 52 out of 192 (27.08%) of UK samples. The presence of this pseudogene is strongly associated with higher copy number of*CCL3L1/CCL4L1* (P\<1 ×10^-10^) (Figure [2](#F2){ref-type="fig"}). The presence of the pseudogene was tested in all HapMap populations (Table [1](#T1){ref-type="table"}). SNP genotyping and*CCL3* microsatellite assays were then carried out to define a set of flanking markers that may predict*CCL3L1/CCL4L1* CN in UK and Basque samples. The best combination of 2 flanking SNPs, rs16972085 and rs8064426, can be used - to predict the*CCL3L1/CCL4L1* CN in UK and Basque samples with only 70% accuracy. Although the*CCL3* microsatellite alleles are not associated with*CCL3L1/CCL4L1* copy number, there is extensive allelic diversity in the microsatellite. Finally, to improve the accuracy of*CCL3L1/CCL4L1* CN prediction, the*CCL3L1/CCL4L1* genes were sequenced in 90 CEU samples to identify sequence variants within the copy-variable genes themselves. Analysis of*CCL3L1/CCL41* haplotypes in CEU samples is underway to provide information on evolution of the*CCL3L1/CCL4L1* haplotypes and the relationship between these haplotypes, flanking SNPs and the presence of the*CCL3L1* pseudogene.
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###### 

Copy number of*CCL3L1/CCL4L1* and presence of *CCL3L1* pseudogene in HapMap populations.

  Samples   Population   Number of samples   Range of *CCL3L1/CCL4L1* CN   Mean *CCL3L1/CCL4L1* CN   Frequency of*CCL3L1* pseudogene positive (%)
  --------- ------------ ------------------- ----------------------------- ------------------------- ----------------------------------------------
  Yoruba    African      90                  2-10                          5                         58 (64.44%)
  CHB-JPT   Asian        90                  1-8                           4                         48 (53.33%)
  CEU       European     90                  0-3                           2                         17 (18.89%)

Conclusion
==========

The*CCL3L1* pseudogene and the combination of SNPs rs16972085 and rs8064426 are associated with the*CCL3L1/CCL4L1* copy number, but the association is not absolute. However, data on evolution of *CCL3L1/CCL4L1* haplotypes and the relationship between these haplotypes, flanking SNPs and the*CCL3L1* pseudogene in CEU samples could provide variable insight to this region.
